2021 · Journal of pediatric gastroenterology and nutrition · paywalled
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients
Zijlstra et al.
The finding, in our words
In paediatric inflammatory bowel disease patients, infliximab levels measured from dried capillary blood spots strongly correlated with venous serum concentrations, with a mean difference of -0.14 μg/mL and excellent interclass correlation coefficient of 0.998. This demonstrates that finger-prick microsampling is a patient-friendly alternative to venepuncture for therapeutic drug monitoring of biologics in children.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The study validated a VAMS-based LC-MS/MS method for measuring sirolimus levels, showing it was clinically equivalent to the standard whole blood method and suitable for therapeutic drug monitoring in paediatric transplant patients, supporting the use of decentralised microsampling for this purpose.
Capillary blood collection using liquid and dried microsampling devices yielded pharmacokinetic profiles comparable to venous sampling for two monoclonal antibodies and a small molecule, whereas haematocrit correction was necessary for dried formats and bridging was ineffective for hydroxychloroquine. The findings demonstrate the bioanalytical feasibility and patient acceptability of remote microsampling tools for pharmacokinetic evaluations in decentralised clinical trials.
A study of 50 paediatric renal transplant recipients found that a validated VAMS LC-MS/MS method for tacrolimus showed high correlation with the reference method over 0.5–60 ng/mL, with minimal haematocrit effect.
Capillary blood sampling using volumetric absorptive microsampling demonstrated non-significant differences in cannabidiol concentrations compared to venous blood and plasma in pediatric patients treated with Epidiolex. The method requires 30 µL of sample, achieves linear quantification between 1 and 800 µg/L, and ensures analyte stability on VAMS devices for up to four weeks at room temperature.
The validated LC-MS/MS method showed similar pharmacokinetic profiles for albendazole and its metabolites across plasma, whole blood, dried blood spots and Mitra microsamples from hookworm-infected adolescents, supporting microsampling for paediatric pharmacokinetic studies. Mitra extraction proved more robust than dried blood spots during validation and is recommended for future albendazole pharmacokinetic work, despite higher albendazole sulfone concentrations observed in both microsampling devices compared with wet matrices.